74 related articles for article (PubMed ID: 28214006)
1. [Conduct of epidemiologic studies in French cancer survivors: Methods, difficulties encountered and solutions provided. Lessons learned from the SIMONAL study on long-term toxicities after non-Hodgkin lymphoma treatment].
Anthony S; Hebel P; Garrel A; Oliveri V; Thieblemont C; Ribrag V; Tilly H; Haioun C; Casasnovas RO; Morschhauser F; Feugier P; Delarue R; Ysebaert L; Sebban C; Broussais F; Damaj G; Nerich V; Jais JP; Salles G; Henry-Amar M; Mounier N
Bull Cancer; 2017 Mar; 104(3):221-231. PubMed ID: 28214006
[TBL] [Abstract][Full Text] [Related]
2. [Hodgkin and non-Hodgkin lymphoma of adolescents and young adults].
Garciaz S; Coso D; Brice P; Bouabdallah R
Bull Cancer; 2016 Dec; 103(12):1035-1049. PubMed ID: 27866679
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
4. [New therapeutic strategies in non-Hodgkin lymphomas and Hodgkin lymphoma].
Rossi C; Bastie JN
Rev Med Interne; 2019 Apr; 40(4):246-254. PubMed ID: 29801709
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
[TBL] [Abstract][Full Text] [Related]
6. Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
Burke JM; van der Jagt RH; Kahl BS; Wood P; Hawkins TE; MacDonald D; Hertzberg M; Simpson D; Craig M; Kolibaba K; Issa S; Munteanu M; Victor TW; Flinn IW
Clin Lymphoma Myeloma Leuk; 2016 Apr; 16(4):182-190.e1. PubMed ID: 26875824
[TBL] [Abstract][Full Text] [Related]
7. Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study.
Nerich V; Guyeux C; Henry-Amar M; Couturier R; Thieblemont C; Ribrag V; Tilly H; Haioun C; Casasnovas RO; Morschhauser F; Feugier P; Sibon D; Ysebaert L; Nicolas-Virelizier E; Broussais-Guillaumot F; Damaj GL; Jais JP; Salles G; Woronoff-Lemsi M; Mounier N
Cancer; 2022 Feb; 128(3):519-528. PubMed ID: 34605020
[TBL] [Abstract][Full Text] [Related]
8. Quality of life among long-term non-Hodgkin lymphoma survivors: a population-based study.
Mols F; Aaronson NK; Vingerhoets AJ; Coebergh JW; Vreugdenhil G; Lybeert ML; van de Poll-Franse LV
Cancer; 2007 Apr; 109(8):1659-67. PubMed ID: 17330853
[TBL] [Abstract][Full Text] [Related]
9. Are lifestyle behavioral factors associated with health-related quality of life in long-term survivors of non-Hodgkin lymphoma?
Spector DJ; Noonan D; Mayer DK; Benecha H; Zimmerman S; Smith SK
Cancer; 2015 Sep; 121(18):3343-51. PubMed ID: 26036473
[TBL] [Abstract][Full Text] [Related]
10. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
11. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database.
Ban-Hoefen M; Vanderplas A; Crosby-Thompson AL; Abel GA; Czuczman MS; Gordon LI; Kaminski MS; Kelly J; Millenson M; Nademanee AP; Rodriguez MA; Zelenetz AD; Niland J; LaCasce AS; Friedberg JW
Br J Haematol; 2013 Nov; 163(4):487-95. PubMed ID: 24111533
[TBL] [Abstract][Full Text] [Related]
12. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study.
Martinelli G; Montoro J; Vanazzi A; Andreola G; Liptrott S; Radice D; Negri M; Preda L; Pruneri G; Laszlo D
Hematol Oncol; 2015 Dec; 33(4):129-35. PubMed ID: 25047267
[TBL] [Abstract][Full Text] [Related]
13. Ambulatory Medical Assistance--After Cancer (AMA-AC): A model for an early trajectory survivorship survey of lymphoma patients treated with anthracycline-based chemotherapy.
Compaci G; Rueter M; Lamy S; Oberic L; Recher C; Lapeyre-Mestre M; Laurent G; Despas F
BMC Cancer; 2015 Oct; 15():781. PubMed ID: 26498342
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of tandem high-dose therapy with autologous stem cell support for adults with high-risk age-adjusted international prognostic index aggressive non-Hodgkin Lymphomas: a GOELAMS pilot study.
Monjanel H; Deconinck E; Perrodeau E; Gastinne T; Delwail V; Moreau A; François S; Berthou C; Gyan E; Milpied N;
Biol Blood Marrow Transplant; 2011 Jun; 17(6):935-40. PubMed ID: 21109011
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
16. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.
Taverna C; Martinelli G; Hitz F; Mingrone W; Pabst T; Cevreska L; Del Giglio A; Vanazzi A; Laszlo D; Raats J; Rauch D; Vorobiof DA; Lohri A; Biaggi Rudolf C; Rondeau S; Rusterholz C; Heijnen IA; Zucca E; Ghielmini M
J Clin Oncol; 2016 Feb; 34(5):495-500. PubMed ID: 26712227
[TBL] [Abstract][Full Text] [Related]
17. Italian cancer figures, report 2012: Cancer in children and adolescents.
; ;
Epidemiol Prev; 2013; 37(1 Suppl 1):1-225. PubMed ID: 23585445
[TBL] [Abstract][Full Text] [Related]
18. Long-term cancer survivors experience work changes after diagnosis: results of a population-based study.
Mols F; Thong MS; Vreugdenhil G; van de Poll-Franse LV
Psychooncology; 2009 Dec; 18(12):1252-60. PubMed ID: 19156675
[TBL] [Abstract][Full Text] [Related]
19. Rituximab with high-dose methotrexate in primary central nervous system lymphoma.
Kansara R; Shenkier TN; Connors JM; Sehn LH; Savage KJ; Gerrie AS; Villa D
Am J Hematol; 2015 Dec; 90(12):1149-54. PubMed ID: 26414492
[TBL] [Abstract][Full Text] [Related]
20. Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study.
Evens AM; Smith MR; Lossos IS; Helenowski I; Millenson M; Winter JN; Rosen ST; Gordon LI
Br J Haematol; 2014 Aug; 166(4):514-20. PubMed ID: 24761968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
